- PharmAla Biotech (CSE:MDMA) has launched its Prescribers Portal for medical practitioners to learn more about MDMA
- The portal is available only to pre-approved medical professionals
- The Prescriber Portal will house tools and resources to help medical practitioners in treating patients
- Shares of PharmAla Biotech are up 10.53 per cent to C$0.21 as of 12:13 pm ET
PharmAla Biotech (CSE:MDMA) has launched a portal for MDMA therapy ahead of the U.S. Food and Drug Administration’s review of MDMA to treat post-traumatic stress disorder (PTSD).
In a news release, the Toronto-based company stated its Prescribers Portal will house tools and resources that will enable medical practitioners to treat patients.
At present, the portal is available only to pre-approved medical professionals.
“As the research and regulatory environment regarding MDMA has moved quickly, most psychiatrists and medical practitioners are seeking information on clinical use and the regulatory pathways for MDMA access available in Canada. We hope our Prescribers Portal will meet this need,” Nicholas Kadysh, CEO of PharmAla Biotech, said in a statement.
The company is also working towards creating an accredited training and continued education module for doctors in Canada and Australia that will summarize technical information related to MDMA’s clinical use.
Friday’s announcement comes one month after PharmAla revealed that its joint venture, Cortexa, began batch manufacturing of MDMA in Australia to support clinical trials and clinical use.
PharmAla Biotech is a biotechnology company focused on the research, development and manufacturing of MDXX-class molecules, including MDMA.
Shares of PharmAla Biotech Holdings Inc. (CSE:MDMA) are up 10.53 per cent to C$0.21 as of 12:13 pm ET.
Join the discussion: Find out what everybody’s saying about this stock on the PharmAla Biotech Holdings Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.